<International Circulation>:What are the advantages of the ASCO classification?

  《国际循环》：ASCO分型的优点是什么？
    Prof Pierre Amarenco: In comparison to TOAST which excluded a lot of patients due to its rigid classification in different subgroups forgetting the underlying disease and any overlap between the diseases ASCO takes into account this overlap and there is no loss of information. 

    皮埃尔教授：TOAST分型标准因对不同亚型的严格划分而忽视了一些潜在疾病以及不同疾病之间的交叉重叠，由此大量患者被排除之外。与之相比ASCO分型充分考虑到了这些交叉因素，不会造成信息丢失。
    <International Circulation>: What is the role of statins in the secondary prevention of stroke?

  《国际循环》：他汀类药物在卒中二级预防中的地位如何？
    Prof Pierre Amarenco: Statins are very important in the prevention of stroke. We have the SPARCL Trial which showed that almost 80mg of statins can prevent the recurrence of stroke and myocardial infarction particularly in patients with atherosclerotic disease classified in A1， A2 and A3 in the ASCO classification. In our cohort 86% of patients with stroke have some form of atherosclerotic disease so 86% of them should be on statins.
Professor Pierre Amarenco is the Chairman of the Department of Neurology at Bichat University Hospital Paris and was an invited speaker at TISC 2010.

    皮埃尔教授： 他汀类药物对预防卒中非常重要。SPARCL试验表明：ASCO-A1、A2及A3型的AS病变患者服用80mg他汀能够有效预防卒中和心肌梗死复发。我们的研究队列中86%的卒中患者都存在不同程度的AS病变，这些患者都应服用他汀类药物。